Financial Performance - For the nine-month period ended September 30, 2025, the company reported revenues of $25,442,000, a 42% increase compared to $17,910,000 for the same period in 2024[6] - The gross profit for the nine-month period was $15,251,000, representing a 55% increase from $9,819,000 in the prior year[6] - Operating loss for the nine-month period was $4,454,000, a decrease from $5,302,000 in the same period of 2024[6] - The Company incurred a net loss of $2,513 for the three months ended September 30, 2025, and a comprehensive loss of $8,931 for the nine months ended September 30, 2025[87][89] - The Company recognized a segment loss of $4,454 for the nine months ended September 30, 2025, with the Products segment loss at $4,051 and CDMO Services at $403[89] Cash Flow and Liquidity - The company had cash and cash equivalents of $10,966,000 as of September 30, 2025, significantly up from $2,390,000 at the end of 2024[4] - The company incurred negative cash flows from operating activities of $4,974,000 for the nine-month period ended September 30, 2025[12] - The net proceeds from the Equity Offering and other events are expected to significantly strengthen the Company's liquidity position and support ongoing operations[25] Equity and Financing - The company completed an equity offering in September 2025, resulting in net proceeds and debt reduction of approximately $14,202,000[22] - The Company completed a Public Offering on November 10, 2025, resulting in gross proceeds of approximately $19.93 million and net proceeds of approximately $18.44 million after deductions[24] - The Company borrowed $1.68 million from private investors during the nine-month period ended September 30, 2025, with interest rates of 16% and 20%[52] - The outstanding balance of short-term loans as of September 30, 2025, is $3.08 million, with $678,000 at a 16% interest rate and $2.40 million at a 20% interest rate[52] - The Company issued 1,146,474 common shares as a result of the conversion of convertible loans, increasing share capital by $7.09 million[43] - The Company extended 503,033 Early Conversion Warrants and 257,143 Major Investor Warrants for an additional 24 months as part of its financing strategy[60] Revenue Segmentation - For the nine months ended September 30, 2025, total revenues were $25,442, with the Products segment at $24,134 and CDMO Services at $1,308[89] - For the three months ended September 30, 2025, external revenue from North America was $7,836 million, compared to $6,009 million in 2024, indicating an increase of 30.4%[96] - For the nine months ended September 30, 2025, external revenue from North America was $22,609 million, up from $16,321 million in 2024, representing a growth of 38.5%[91] - The Company has no single customer contributing 10% or more of total revenue for the three and nine months ended September 30, 2025, and 2024[92] Assets and Deficits - The company's accumulated deficit as of September 30, 2025, reached $105,349,000, up from $96,418,000 at the end of 2024[4] - The total assets increased to $35,188,000 as of September 30, 2025, compared to $25,001,000 at the end of 2024[4] Operational Focus - The Company is focused on developing therapeutic solutions using its Botanical Synthesis Platform Technology, which allows for the production of active ingredients without traditional agriculture[19] - The Company has not experienced any material impact on operations due to recent geopolitical events as of the date of the financial statements[31] Shareholder Actions - As of September 30, 2025, the Company issued and outstanding common shares increased to 19,616,380 from 17,327,716 as of December 31, 2024[42] - The Company granted 78,712 options at an exercise price of $9.00 and 18,572 options at $8.30 during the period, with total values of $284 and $79 respectively[48] - The exercise price of certain warrants was reduced from $7.77 and $11.52 to $6.50 per share as part of the Equity Offering[43] - The Company issued 1,786 common shares on October 14, 2025, from employee and consultant options, generating proceeds of $9 million[96] - Following September 30, 2025, the Company issued 189,279 common shares from warrant exercises, resulting in proceeds of $1,108 million[96]

Core Insights - BioHarvest Sciences Inc. will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY [2] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during the event [3] - The company is experiencing strong momentum in both its consumer and CDMO divisions, with robust performance in its core VINIA® capsule business and new product lines [4] Company Performance - BioHarvest's VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution are expanding the company's market reach [4] - The CDMO platform has achieved significant milestones, including advancements in plant-based exosome production and a new contract for developing a saffron compound [4] - The company successfully closed a $19.9 million equity offering, which is expected to support its goal of achieving adjusted EBITDA breakeven in the near term [4] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - BioHarvest Sciences Inc. has successfully closed a public offering of common stock, raising $19.9 million to support its growth initiatives and operational needs [2][4]. Group 1: Offering Details - The public offering consisted of 2,846,854 shares at a price of $7.00 per share, including 361,854 shares from the underwriters' option to purchase additional shares [2][3]. - The gross proceeds from the offering amounted to $19.9 million before deducting underwriting discounts and other expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for immediate funding of manufacturing expansion, research and development, marketing, debt reduction or refinancing, capital expenditures, and general corporate purposes, including working capital [3][4]. Group 3: Company Background - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to cultivate the actual plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Points - BioHarvest Sciences Inc. has announced a public offering of 2,485,000 shares of common stock priced at $7.00 per share, aiming for gross proceeds of approximately $17.4 million [1][2] - The company has granted underwriters a 30-day option to purchase an additional 372,750 shares at the public offering price [1] - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on September 8, 2025 [3] Use of Proceeds - The net proceeds from the offering are expected to be utilized for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes, including funding working capital [2] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the underlying plants [5] - The company operates in two major business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Core Viewpoint - BioHarvest Sciences Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. - Craig-Hallum is the sole managing underwriter for the offering [2]. - A preliminary prospectus supplement will be filed with the SEC, detailing the terms of the proposed offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for various purposes, including research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to grow the plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Core Viewpoint - BioHarvest Sciences Inc. will release its third quarter financial results for 2025 on November 13, 2025, after market close, and will host an investor conference call to discuss these results and provide a corporate update [1][2]. Group 1: Earnings Call Details - The earnings call is scheduled for November 13, 2025, at 4:30 p.m. Eastern Time [2]. - Participants can join the call using the U.S./Canada dial-in number 1-877-300-8521 or the international dial-in number 1-412-317-6026, with a conference ID of 6486821 [2]. - A telephone playback of the call will be available until November 27, 2025, and a webcast replay will also be accessible [3]. Group 2: Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to cultivate the actual plants [4]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) for complex molecules and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4].

Core Insights - The article discusses the potential of consumer defensive stocks, highlighting those with more than 50% upside potential in the current market environment [5][10]. Group 1: Market Analysis - Michel Lerner from UBS emphasizes the importance of focusing on quality defensive stocks rather than solely on value stocks, which may carry higher risks in uncertain economic conditions [2][3]. - Defensive stocks, particularly in Europe, have underperformed, resembling trends seen during the dot-com bubble, but are now presenting more attractive valuations [3][4]. - Earnings pressures for some defensive stocks are beginning to ease, providing a hedge in a risk-on market environment [4]. Group 2: Stock Recommendations - JBS N.V. (NYSE:JBS) has an analyst upside of 51.40% with a price target set at $20 by Bank of America Securities, despite recent adjustments to EBITDA and EPS forecasts due to challenges in the US chicken market [10][11][12]. - BioHarvest Sciences Inc. (NASDAQ:BHST) shows an analyst upside of 51.52% and has entered a strategic agreement with Saffron Tech to develop saffron-derived compounds, aiming for large-scale production and direct-to-consumer marketing [13][15][16].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in major cities such as London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - The company is committed to using technology to enhance workflows and improve content production [4] - Proactive employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]